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The immunomodulatory properties of yeast β-1,3/1,6 glucans are mediated through their
ability to be recognized by human innate immune cells. While several studies have investi-
gated binding of opsonized and unopsonized particulate β-glucans to human immune cells
mainly via complement receptor 3 (CR3) or Dectin-1, few have focused on understanding
the binding characteristics of soluble β-glucans. Using a well-characterized, pharmaceutical-
grade, soluble yeast β-glucan, this study evaluated and characterized the binding of soluble
β-glucan to human neutrophils and monocytes. The results demonstrated that soluble β-
glucan bound to both human neutrophils and monocytes in a concentration-dependent and
receptor-specific manner. Antibodies blocking the CD11b and CD18 chains of CR3 signifi-
cantly inhibited binding to both cell types, establishing CR3 as the key receptor recognizing
the soluble β-glucan in these cells. Binding of soluble β-glucan to human neutrophils and
monocytes required serum and was also dependent on incubation time and temperature,
strongly suggesting that binding was complement-mediated. Indeed, binding was reduced
in heat-inactivated serum, or in serum treated with methylamine or in serum reacted with
the C3-specific inhibitor compstatin. Opsonization of soluble β-glucan was demonstrated
by detection of iC3b, the complement opsonin on β-glucan-bound cells, as well as by the
direct binding of iC3b to β-glucan in the absence of cells. Binding of β-glucan to cells was
partially inhibited by blockade of the alternative pathway of complement, suggesting that
the C3 activation amplification step mediated by this pathway also contributed to binding.
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INTRODUCTION
Yeast β-glucans are represented in various forms such as
intact yeast, zymosan, purified whole glucan particle, solubilized
zymosan polysaccharide, or highly purified soluble β-glucans of
different molecular weights (1–11). Structurally, yeast β-glucans
are mainly composed of glucose monomers organized as a β-
(1-3)-linked glucopyranose backbone with periodic β-(1-3) glu-
copyranose branches linked to the backbone via β-(1-6) glycosidic
linkages. Studies of the mechanisms through which the yeast β-
glucans exert their immunomodulatory effects have largely been
focused on evaluation of the most basic and simple structural
differences between β-glucans, such as their particulate or sol-
uble nature, to the more complex structural characteristics that
determine the tertiary conformation including, length of the main
chain, length of the side chains, and frequency of the side chains.
Yeast β-glucans are fungal pathogen associated molecular pat-
terns (PAMPs) and are recognized by pattern recognition recep-
tors on cellular membranes as well as pattern recognition mole-
cules in the serum. Complement receptor 3 (CR3, CD11b/CD18,
αMβ2-integrin, Mac-1) and Dectin-1 have been reported to
be the predominant cell surface pattern recognition receptors
for yeast β-glucans on innate immune cells including, mono-
cytes, macrophages, dendritic cells, and neutrophils (1–9). Several
studies have shown that both particulate β-glucans as well as var-
ious forms of yeast-derived soluble β-glucans bind to both CR3
and Dectin-1 (1, 2, 4, 12–16). Soluble zymosan polysaccharide
(SZP), rich in mannan or β-glucan (∼10 kDa), neutral soluble
glucan (∼25 kDa, NSG), a chemically modified soluble yeast β-
glucan (∼127 kDa, glucan phosphate) have all been shown to
bind to CR3 on human peripheral blood isolated neutrophils (7,
8). Of these, glucan phosphate and NSG have also been used as
antagonists of Dectin-1 receptor (3, 4, 17, 18). The highly puri-
fied soluble β-(1,6)-[poly-(1,3)-d-glucopyranosyl]-poly-β(1,3)-
d-glucopyranose (PGG) glucan (∼120–205 kDa) has also been
demonstrated to bind to recombinant human Dectin-1 and signal
via CR3 on human neutrophils (17, 19).
With respect to pattern recognition molecules in serum, com-
plement proteins can recognize pathogens and subsequently be
activated by the classical, alternative,or lectin pathways (20, 21). All
three culminate in activation of C3, the central step in complement
activation, which is then followed in the final steps by formation
of the cytolytic membrane attack complex (MAC). After the initial
C3 proteolytic activation step, nascently activated C3b can cova-
lently associate with the carbohydrates or proteins present on the
surface of the pathogen. This initial process of C3b attachment to
pathogens is followed by further inactivation of bound C3b by its
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proteolysis to iC3b, followed by further degradation to C3d (20,
21). Complement opsonization of pathogens can lead to either
direct killing of the pathogen by formation of MAC or recogni-
tion and destruction of the C3 fragment-opsonized pathogen by
cell-associated complement receptors, CR1, CR2, CR3, or CR4 on
leukocytes. Zymosan, a crude particulate β-glucan obtained from
cell walls of Saccharomyces cerevisiae is well known as a stimulator
of the antibody-independent alternative pathway of complement
activation (22–25). β-glucan from Candida albicans, a pathogenic
fungus has also been shown to activate the alternative pathway of
complement (26). Some studies have also shown a role for both the
classical and the alternative pathways in opsonization of zymosan
and glucan from the fungi Cryptococcus neoformans and Blasto-
myces dermatitidis (27–31). Curdlan, a linear β-1,3 glucan coupled
to a resin has been demonstrated to be recognized by MBL and
l-ficolin in human serum and to activate the lectin pathway of
complement activation (32).
In binding studies to date, both complement opsonized and
unopsonized fungus, and particulate β-glucans have been demon-
strated to bind to CR3, CR4, and Dectin-1 (1, 2, 4, 12–16, 33).
However, the role of complement opsonization in binding of
soluble β-glucan to CR3 or Dectin-1 has not been studied. In
this report we have investigated the binding of Saccharomyces
cerevisiae-derived, highly purified, well-characterized soluble β-
glucan, PGG β-glucan, to human monocytes and neutrophils, the
innate immune cells expressing the reported β-glucan receptors.
The results confirm some of the earlier findings that binding of
soluble yeast β-glucan to human monocytes and neutrophils is
CR3-mediated. In addition, we also demonstrate that the solu-
ble β-glucan binds to CR3 in a complement-dependent manner.
Complement opsonization of the soluble β-glucan was shown to
be a critical requirement for its binding to the immune cells.
MATERIALS AND METHODS
ANTIBODIES AND REAGENTS
The list of antibodies (Abs) used in the study as well as their source
and specificities are shown in Table 1. Antibody-sensitized sheep
erythrocytes (EA), MicroVue SC5b-9 Plus EIA kit, and MicroVue
C4a EIA kit were from Quidel (San Diego, CA, USA). Comp-
statin (ICVVQDWGHHRCT) and control peptide (IAVVQD-
WGHHRAT) were from Tocris Bioscience (Bristol, UK). Dex-
tran, ethylene glycol tetraacetic acid (EGTA), magnesium chloride
(MgCl2), and 4′,6-diamidino-2-phenylindole (DAPI) were from
Sigma Aldrich (St. Louis, MO, USA). Pyrogene™ endotoxin kit
was purchased from Lonza (Walkersville, MD, USA).
PREPARATION AND CHARACTERIZATION OF β-GLUCAN
PGG β-glucan, a pharmaceutical-grade soluble yeast 1,3/1,6 β-
glucan was manufactured from a strain of Saccharomyces cerevisiae
generated by Biothera (Eagan, MN, USA). As part of the manufac-
turing and quality control process, PGG β-glucan was extensively
characterized analytically with respect to the parameters listed in
Table 2. For some experiments, PGG β-glucan was prepared for
use by performing a buffer exchange into Dulbecco’s phosphate-
buffered saline (DPBS) using 3 kDa molecular weight cut-off
(MWCO) Amicon centrifugal filtration units (Millipore, Billerica,
Table 1 | Description of antibodies used in the study.
Designation Isotype Specificity Source
HI111 Murine IgG1 mAb Human CD11a eBioscience (San Diego, CA)
LM2/1 Murine IgG1 mAb Human CD11b (I-domin) eBioscience
VIM12 Murine IgG1 mAb Human CD11b (Lectin-like domain) Invitrogen (Camarillo, CA)
IB4 Murine IgG2a mAb Human CD18 Ancell (Bayport, MN)
GE2 Murine IgG1 mAb Human Dectin-1 AbD Serotec (Raleigh, NC)
iC3b Murine IgG2b mAb Human iC3b (neo antigen) Quidel (San Diego, CA)
166–32 Murine IgG1 mAb Human factor D ATCC (Manassas, VA)
BfD IV Murine IgM mAb Yeast β-1,3/1,6-glucan Biothera (Eagan, MN)
CD14 Murine IgG1 mAb Human CD14 BioLegend (San Diego, CA)
CD15 Murine IgG1 mAb Human CD15 BioLegend
IgG1 Murine IgG1 Isotype control eBioscience
IgG2a Murine IgG2a Isotype control eBioscience
FITC-conjugated F(ab′)2 Goat
anti-Mouse IgM
Goat polyclonal Mouse IgM Jackson ImmunoResearch Lab (West Grove, PA)
Cy3-conjugated Goat
anti-mouse IgG
Goat polyclonal Mouse IgG BioLegend
Cy3-conjugated Goat
anti-mouse IgM
Goat polyclonal Mouse IgM Jackson ImmunoResearch Lab
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Table 2 | Analytical characterization of PGG β-glucan.
Parameters Results
Average molecular weighta 150,000 Da
Branchingb 4.1%
Purityc
Residual Proteind ≤0.2%
% Mannans (mannose)e ≤0.6%
% Glycogenf ≤5%
% Chitin (glucosamine)g ≤0.4%
aGel permeation chromatography (GPC) with differential refractive index (dRI) and
multi angle laser light scattering (MALLS) detection.
bPartially methylated alditol acetate method using gas chromatography with flame
ionization detection.
cExpressed as % of total hexose.
dDetection by Bradford protein assay.
eHydrolysis with trifluoroacetic acid to monosaccharides followed by high perfor-
mance anion exchange chromatography with pulsed amperometric detection.
fDigestion by amyloglucosidase and detection of liberated glucose by an enzy-
matic glucose detection assay.
gHydrolysis with sulfuric acid followed by reaction with acetyl acetone and
Ehrlich’s reagent and detection spectrophotometrically.
MA, USA). The hexose concentration of the β-glucan preparations
was determined by the anthrone method (34). Preparation of
particulate β-glucan has been described previously (35, 36).
ISOLATION OF HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS
AND NEUTROPHILS
Heparinized venous blood was obtained from healthy individ-
uals with informed consent as approved by the Institutional
Review Board (approved by the New England Institutional Review
Board,Wellesley, MA, USA, Blood Donation Protocol No. 07-124).
Briefly, peripheral blood mononuclear cells (PBMC) were isolated
by Ficoll-Paque (Amersham Biosciences, Piscataway, NJ, USA)
density gradient centrifugation. Neutrophils were subsequently
enriched by sedimentation with 3% dextran, followed by hypo-
tonic lysis of residual erythrocytes. The purity and viability of
neutrophils and PBMC obtained were consistently>95%.
PREPARATION OF HUMAN AUTOLOGOUS SERUM
Human serum was prepared according to vendor’s instruction.
Ten milliliters of non-heparinized whole blood (WB) was added
to a Vacutainer® SSTTM tube (Becton Dickinson, NJ, USA) and
inverted 3–5 times. The blood was allowed to clot by incubation at
room temperature for 30 min, and then the sample was centrifuged
at 2000 rpm (∼1150× g ) for 10 min and cleared serum was col-
lected and used as needed. For preparing heat-inactivated (HI)
serum, the serum was incubated in a 56°C water bath for 30 min.
All binding experiments were performed using autologous serum.
In this study, autologous (complement-intact) human serum will
be hereafter referred to as serum and after heating, as HI serum.
PGG β-GLUCAN BINDING STUDIES
Enriched neutrophils or PBMC were resuspended at 1× 106
cells/milliliters in RPMI 1640 supplemented with 10% human
serum. In dose-titration studies, PGG β-glucan at hexose concen-
trations 10, 25, 100, 200, or 400µg/mL were added to neutrophils
or PBMC and incubated in a 37°C, 5% CO2 humidified incuba-
tor for 1 h. In subsequent experiments, PGG β-glucan was added
at 100µg/mL to both neutrophils and PBMC. After incubation,
cells were washed twice with FACS buffer (HBSS supplemented
with 1% fetal bovine serum and 0.1% sodium azide) to remove
any unbound β-glucan, and subsequently treated with Fc block
(Miltenyi Biotec, Auburn, CA, USA). After the Fc block step,
cells were stained with the BfD IV mouse IgM mAb for 30 min
at 4°C and washed twice with cold FACS buffer. Cells were
then incubated with FITC-conjugated F(ab′)2 goat anti-mouse
IgM for 30 min at 4°C and washed once with cold FACS buffer
before fixing with 1% paraformaldehyde. The generation and
specificity of Biothera-produced β-1,3/1,6-glucan-specific mAb
BfD IV (mouse IgM, clone 10C6) has been described previ-
ously (37). In certain optimization experiments, neutrophils and
monocytes were identified by staining with fluorescently labeled
anti-CD15, or anti-CD14 Abs respectively. Events were collected
on a LSRII flow cytometer (BD Biosciences, San Jose, CA, USA)
and analysis was performed using FlowJo (Tree Star, Ashland, OR,
USA).
CR3 AND DECTIN-1 BINDING STUDIES
To evaluate the role of CR3 or Dectin-1 receptors in binding, the
cells were pre-incubated with specific receptor blocking Abs or
the relevant isotype controls at 4°C for 30–45 min before addi-
tion of 100µg/mL PGG β-glucan and measurement of binding
was performed as described earlier. The CR3 blocking Abs used
were LM2/1, a mouse anti-human IgG1 monoclonal antibody
to the I-domain of the CD11b chain of CR3, VIM12, a mouse
monoclonal IgG1 anti-human antibody to the lectin domain of
the CD11b chain of CR3, and IB4, a mouse monoclonal IgG2a
anti-human antibody to the CD18 chain of CR3. Each block-
ing Ab was used at 10µg/1× 106 cells. Combinations of CR3
blocking Abs used were either LM2/1+VIM12 to block both the
I-domain and lectin-domains of the CD11b subunit or LM2/1+
VIM12+ IB4 to block both the CD11b and CD18 subunits of
CR3. HI111, a mouse monoclonal IgG1 anti-human antibody to
an irrelevant integrin, the CD11a chain of LFA-1 was used at
10µg/mL as a negative control in some of the blocking experi-
ments. For blocking the Dectin-1 receptor, clone GE2, a mouse
monoclonal IgG1 anti-human antibody was used at 10µg/mL. All
the isotype controls were used at the same concentration as the
blocking Abs.
BINDING STUDIES TO DETERMINE SERUM, TIME, AND TEMPERATURE
DEPENDENCY
For these experiments, PGG β-glucan was used at 100µg/mL and
binding determined as described above with the following changes.
For determining serum dependency, PGG β-glucan was incubated
with cells resuspended in RPMI 1640 containing either 2, 5, 10, 20,
or 50% serum at 37°C for 1 h. For kinetic experiments, PGG β-
glucan was incubated with cells resuspended in 10% serum at 37°C
for 10, 30, 60, or 120 min. For temperature dependency exper-
iments, PGG β-glucan was incubated with cells resuspended in
10% serum for 1 h at 4°C, room temperature, or 37°C.
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BINDING OF PGG β-GLUCAN AFTER PRE-OPSONIZATION
Here pre-opsonization of β-glucan is defined as the process of
incubating PGG β-glucan in serum before adding the β-glucan
to neutrophil or PBMC cultures containing serum. One part PGG
β-glucan was added to nine parts serum at a final β-glucan concen-
tration of 6–8 mg/mL and incubated for 30 min at 37°C in a water
bath. The serum-pretreated β-glucan (OpPGG) was then added
to cells to obtain a final concentration of 100µg/mL. At this con-
centration, the final concentration of serum transferred into the
cell cultures amounted to less than 2%. The ability of OpPGG to
bind to the cells at 37°C, after resuspension in 10% serum or in HI
serum was subsequently measured.
BINDING STUDIES TO DETERMINE THE ROLE OF SERUM COMPLEMENT
PROTEINS
To determine the role of serum complement in binding of PGG
β-glucan, experiments were performed as described above except
for variation to the serum conditions. Serum conditions used in
these studies included 10% HI serum, compstatin-treated serum,
EGTA+MgCl2 (MgEGTA)-treated serum, or factor D-blocked
serum. For compstatin- and control peptide-treated serum, comp-
statin or the control peptide was added to the serum at 20 or
100µM and incubated at room temperature for 10 min. For block-
ing of factor D in the serum, 166–32 mAb at a concentration of
20µg/mL was incubated with serum on ice for 30 min, and then
used for binding studies. For binding experiments in the pres-
ence of MgEGTA, serum was incubated with 10 mM EGTA with
10 mM MgCl2 for 10 min at room temperature. The untreated
and MgEGTA-treated serum was then used to pre-opsonize PGG
β-glucan and perform binding studies as described above.
iC3b STAINING ON PGG β-GLUCAN-BOUND CELLS
Binding of PGG β-glucan to neutrophils and PBMC was per-
formed as described above. iC3b deposition on these cells was
detected by staining with a neo-epitope specific anti-iC3b mAb
and PE-conjugated goat anti-mouse IgG followed by flow cytom-
etry analysis.
ELISA FOR iC3b DEPOSITION ON IMMOBILIZED PGG β-GLUCAN
PGG β-glucan or dextran were immobilized on wells of a 96 well
polystyrene Costar®plate (Corning, NY, USA) by drying at 50°C
followed by ultra-violet cross-linking. The coated plates were first
blocked with 1% BSA before incubation with the untreated serum
or serum that had undergone various treatments as described in
binding studies. For this step, the serum was diluted 1:2 with
wash buffer (PBS/0.05% Tween-20) and plates were incubated for
30 min at 37°C. Each treatment condition was performed in trip-
licate. After washing off the serum from the plate, bound iC3b
was detected by using the anti-iC3b mAb followed by biotin-
labeled goat anti-mouse IgG Ab. Binding of the biotin-labeled anti-
body was determined using streptavidin peroxidase and 3,3′,5,5′-
Tetramethylbenzidine substrate solution (KPL, Gaithersburg, MD,
USA). Optical density at 450 nm (OD450) of each well was mea-
sured with a SpectraMAX 250 (Molecular Devices, CA, USA). The
fold change was calculated by dividing the OD450 of wells contain-
ing immobilized PGG β-glucan or dextran by the OD450 of blank
wells, incubated in the presence of treated or untreated serum.
IMMUNOPRECIPITATION OF PGG β-GLUCAN
One part PGG β-glucan was added to nine parts serum or HI
serum at a final β-glucan concentration of 6–8 mg/mL and incu-
bated for 30 min at 37°C in a water bath. BfD IV mAb was added
to the serum-glucan mixture and incubated at room tempera-
ture for an additional 30 min. Magnetic beads conjugated with
rat anti-mouse IgM (Dynabeads) were washed three times with
DPBS and incubated with the serum-PGG β-glucan/dextran-BfD
IV mixture for another 30 min at room temperature. The beads
were separated magnetically and any iC3b that was pulled-down
along with the immunoprecipitated PGG β-glucan was detected
by flow cytometry using FITC-conjugated iC3b mAb.
MEASUREMENT OF FLUID-PHASE SC5b-9 COMPLEX FORMATION IN
THE SERUM
The MicroVue SC5b-9 EIA kit was used to measure activation of
the classical and alternative pathways of complement according
to the vendor’s instruction (Quidel). Briefly, the serum (untreated
or various treated serum preparations) was mixed with PBS, EA,
or 20 units of cobra venom factor (CVF) and added to the plate
wells pre-coated with anti-SC5b-9 mAb. The plate was incubated
at 37°C for 60 min followed by five washes with the provided wash
buffer. The plate was then incubated at room temperature for
30 min with the provided SC5b-9 Plus Conjugate that contained
a horseradish peroxidase-conjugated Ab specific for SC5b-9. The
plate was then washed five times, incubated with the substrate (see
above) for 15 min at room temperature to initiate the enzymatic
reaction and subsequently quenched with the stop solution. OD450
was measured. The concentration of fluid-phase SC5b-9 present
in the samples was determined from the standard curve generated
with the provided SC5b-9 standards.
MEASUREMENT OF C4a LEVELS
The MicroVue C4a EIA kit to measure C4a levels in the plasma
was used according to the vendor’s instruction (Quidel). Briefly,
WB was either treated with vehicle, or, 10µg/mL PGG β-glucan,
or 10µg/mL particulate β-glucan at 37°C for 30 min. After stim-
ulation, WB was spun for 5 min at 2000 rpm and cell-free plasma
was collected. Plasma samples were added to the plate wells pre-
coated with anti-C4a mAb. The plate was incubated at 37°C for
60 min followed by five washes with the provided wash buffer. The
plate was then incubated at room temperature for 60 min with the
provided Conjugate reagent containing a horseradish peroxidase-
conjugated Ab specific for C4a. The plate was then washed five
times, incubated with the substrate reagent for 15 min at room
temperature to initiate the enzymatic reaction, and subsequently
quenched with the stop solution. OD450 was measured. The con-
centration of C4a present in the samples was determined from the
standard curve generated with the provided C4a standards.
CONFOCAL MICROSCOPY
Enriched neutrophils resuspended at 1× 106 cells/milliliters in
RPMI supplemented with 20% serum or HI serum were mixed
with PGG β-glucan before applying onto 10 mm glass cover slips
placed in the wells of a 24 well plate. The plate was incubated in
a 37°C, humidified 5% CO2 incubator for 1 h. Unbound cells and
PGG β-glucan were removed by washing with warmed PBS, and
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bound cells were subsequently fixed in 1% paraformaldehyde at
room temp for 15 min. Cells were blocked with Fc block prior to
staining with BFD IV and anti-iC3b mAb for 30 min at 4°C. The
cells were then stained by secondary Abs, Cy5-conjugated goat
anti-mouse IgM and Cy3-conjugated goat anti-mouse IgG at 4°C
for 30 min. Cells were permeabilized with 0.1% ice-cold TritonX-
100 for 3 min on ice and stained with DAPI on ice for 5 min before
mounting onto slides. Images were analyzed and acquired with
an Olympus FluoView 1000 IX2 Inverted confocal microscope.
Images were adjusted equally in Adobe Photoshop (Adobe Systems
Inc., San Jose, CA, USA).
DATA ANALYSIS
The neutrophils and monocytes were assessed for their capacity to
bind PGG β-glucan by comparing the mean fluorescence inten-
sity (MFI) of the cells stained with the anti-β-glucan antibody,
BfD IV and the percentage of cells positive for BfD IV relative to
values obtained in vehicle-treated control group. For inhibition
of binding studies, Percent inhibition of Imprime PGG binding is
calculated based on MFI values of BfD IV positive cells in the pres-
ence and absence of blocking Abs. The formula used for calculating
percent inhibition is:(
MFIPGG−treated group with controls−MFIvehicle
)−(
MFIPGG−treated group with inhibitory agents−MFIvehicle
)(
MFIPGG−treated group with controls−MFIvehicle
)
Statistical analysis to compare different treatment groups to each
other were done by performing Student t -test; p≤ 0.05 was
considered significant.
RESULTS
PGG β-GLUCAN BINDS TO HUMAN NEUTROPHILS ANDMONOCYTES IN
A CR3-DEPENDENT MANNER
The binding of PGG β-glucan to human neutrophils and mono-
cytes was evaluated by incubating 10, 25, 100, 200, and 400µg/mL
of PGG β-glucan or vehicle with the cells resuspended in media
with 10% serum, and then staining the cells with a β-glucan-
specific mAb, BfD IV plus a fluorophore labeled secondary anti-
body. These concentrations were chosen to evaluate in vitro bind-
ing of PGG β-glucan at concentrations on both the lower and
higher side of the maximum concentration achieved in the serum
(Cmax) of healthy volunteers and cancer patients administered
PGG β-glucan. To date, the range of Cmax values observed in
healthy volunteers is 35.49–66.5µg/mL with the average being
51.24± 15.45µg/mL, while in cancer patients, this range is 18.3–
62.4, with the average being 39.5± 19.2µg/mL (unpublished data
from clinical trials NCT00542217 and NCT00545545). As shown
in Figure 1A, PGG β-glucan at concentrations bound to both neu-
trophils and monocytes in a dose-dependent manner. While for
both cell types, the percentage of BfD IV positive cells reached a
plateau at 200µg/mL, the MFI values continued to increase with
increasing concentrations of PGG β-glucan. The variability in the
extent of PGG β-glucan binding to the neutrophils and monocytes
in multiple donors as demonstrated by the variability in the MFI
values achieved is shown in Figure S1 in Supplementary Material.
FIGURE 1 | Role of CR3 receptor in binding of PGG β-glucan to
human neutrophils and monocytes. (A) Binding of increasing
concentration of PGG β-glucan (0, 10, 25, 100, 200, and 400µg/mL) to
human neutrophils (upper row) and monocytes in PBMC (lower row)
was measured by flow cytometry after incubation of cells with β-glucan
or vehicle at 37°C for 1 h. (B) To identify the receptor involved, binding
of PGG β-glucan to human neutrophils (left) and monocytes (right) was
measured in the presence of α-CD11b (upper row), α-CR3 (second
row), α-CD11a (third row), or α-Dectin-1 blocking antibodies (bottom
row). The MFI and percentage of β-glucan-treated, BfD IV positive cells
are indicated in the zebra plots. Histograms show PGG β-glucan binding
in the presence of isotype controls (solid) and blocking antibodies
(dotted) compared to vehicle-control binding (gray filled). Bars represent
the mean MFI of the vehicle- or PGG β-glucan-treated groups in the
presence of CR3 blocking or isotype control antibodies from five
donors. The percentage of inhibition (in parentheses) was indicated on
the graph. **p≤0.05 compared to β-glucan-treated group in the
presence of isotype controls. Data shown are representative of at least
three independent experiments performed with cells from different
donors.
www.frontiersin.org August 2013 | Volume 4 | Article 230 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bose et al. Complement and soluble β-glucan binding
In order to determine the role of CR3 or Dectin-1 in the
binding of PGG β-glucan to human neutrophils and monocytes,
these receptors were blocked with receptor-specific blocking Abs
or irrelevant control Abs before addition of PGG β-glucan and
measurement of binding. Data presented in Figure 1B shows
that blocking the CD11b chain (LM2/1+VIM 12) of CR3 par-
tially inhibited binding of PGG β-glucan to both neutrophils and
monocytes, while blocking both the CD11b and CD18 chains
(LM2/1+VIM12+ IB4) of CR3 further inhibited PGG β-glucan
binding. Blocking the alpha chain of a non-specific integrin,
CD11a chain of LFA-1, did not affect PGG β-glucan binding.
Moreover, blocking the other major β-glucan receptor, Dectin-
1 (GE2), did not inhibit PGG β-glucan binding to neutrophils
or monocytes. Based on results from five different donors, the
average MFI of BfD IV positive cells treated with CR3 blocking
Abs (LM2/1+VIM12+ IB4) was significantly lower than that of
the BfD IV positive cells treated with the isotype control Abs.
Based on the MFI values in these five donors, a percentage of
inhibition of binding by the CR3 blocking Abs was calculated rel-
ative to that of the isotype control Abs in these five donors. The
range of percentage of inhibition of binding by blocking both
of the CR3 chains in neutrophils was 69–100% with an aver-
age inhibition of 80%, and in monocytes the range was 42–95%
with an average of 75%. Overall, the results demonstrate that
in the presence of serum, CR3 plays a major role as a receptor
involved in the binding of PGG β-glucan to human neutrophils
and monocytes.
BINDING OF PGG β-GLUCAN TO HUMAN NEUTROPHILS AND
MONOCYTES IS SERUM-, TIME-, AND TEMPERATURE-DEPENDENT
In order to determine the conditions required for PGG β-glucan
binding to human neutrophils and monocytes, the influence of
serum, time, and temperature were evaluated. The role of serum
in PGG β-glucan binding to cells was evaluated after incubating
cells at 37°C for 1 h in media with 2, 5, 10, 20, or 50% serum.
The data in Figure 2A demonstrate that binding of PGG β-glucan
increased proportionally with the percentage of serum present
in the media. At the tested serum concentrations, minimum and
maximal binding occurred on neutrophils at 2 and 50% serum,
respectively. However, for monocytes, the maximum binding was
observed at 10% serum, while a reduction in binding was seen at
20 and 50% serum. The variability in binding of PGG glucan at
the different serum concentrations in multiple donors as demon-
strated by the variability in the MFI achieved is demonstrated in
Figure S2 in Supplementary Material. The effects of incubation
time and temperature on PGG β-glucan binding were evaluated
under conditions using media containing 10% serum. In kinetic
experiments, binding was measured at 10, 30, 60, and 120 min of
incubation at 37°C. To evaluate the influence of temperature, bind-
ing was measured after cells were incubated with PGG β-glucan
for 1 h at 4°C, room temperature, or 37°C. The results presented
in Figure 2B demonstrate that PGG β-glucan binding increases
with incubation time. For neutrophils, optimal binding occurred
at 30–60 min, while 60–120 min were required for optimal bind-
ing to monocytes. Temperature also affected the binding of PGG
β-glucan to cells; optimal binding occurred when PGG β-glucan
was incubated with cells at 37°C as compared to 4°C or room
FIGURE 2 |Time, temperature, and serum-dependent binding of PGG
β-glucan to human neutrophils and monocytes. PGG β-glucan binding to
human neutrophils and monocytes was determined (A) in the presence of
2, 5, 10, 20, and 50% of serum, (B) at 10, 30, 60, and 120 min, and (C) at
RT, 4 and 37°C. The MFI and percentage of BfD IV positive cells were
indicated in the zebra plots, and histogram shows PGG β-glucan binding
(solid) in comparison to the vehicle-control (gray filled). Data shown in each
of the conditions are representative of three independent experiments
performed with cells obtained from three different donors.
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temperature (Figure 2C). These data demonstrate that binding of
PGG β-glucan to human neutrophils and monocytes is serum-,
time-, and temperature-dependent.
BINDING OF SOLUBLE PGG β-GLUCAN TO HUMAN NEUTROPHILS AND
MONOCYTES IS DEPENDENT ON COMPLEMENT
After evaluating the importance of serum in the binding of PGG
β-glucan, we next investigated the role that serum complement
plays in binding. This was performed by (a) heat inactivat-
ing serum which non-specifically inactivates complement, and
(b) specifically blocking C3, the complement protein central to
the classical, alternate, and lectin complement pathways, with
compstatin (38).
As shown in Figure 3A, binding of PGG β-glucan to both neu-
trophils and monocytes was reduced when the serum was HI.
Based on MFI values from five separate donors, the percentage
of inhibition of binding in HI serum was found to be 71–100%
with an average inhibition of 90%, and in monocytes the inhi-
bition range was 81–100% with an average of 96%. The data in
Figure 3B further show that specifically blocking activation of C3
using varying concentrations of compstatin inhibited binding of
PGG β-glucan in a concentration-dependent manner, with max-
imum inhibition observed at 100µM. The control peptide had
no effect on binding of PGG β-glucan on monocytes, but for rea-
sons unknown, binding on neutrophils non-specifically increased
in the presence of peptide control. Based on MFI values from
three separate donors, the percentage of inhibition of binding by
compstatin in neutrophils was 90–98% with an average inhibition
of 95%, in monocytes the range was 62–92% with an average of
80%. Taken together, these data conclusively show that comple-
ment plays a critical role in binding of soluble PGG β-glucan to
human neutrophils and monocytes.
SERUM, TIME, AND TEMPERATURE REQUIREMENT FOR BINDING OF
PGG β-GLUCAN TO HUMAN NEUTROPHILS AND MONOCYTES IS
PRIMARILY AT THE LIGAND LEVEL AND NOT AT THE RECEPTOR LEVEL
The findings of optimal serum content, incubation time, and tem-
perature, together with the critical requirement of complement for
binding of PGG β-glucan, led us to hypothesize that PGG β-glucan
is opsonized by complement proteins. To test this hypothesis, we
first investigated whether the dependency on time, temperature,
and serum is indeed at the ligand (i.e., PGG β-glucan) level and
not at the receptor (i.e., CR3) level. To discern the influence of
serum, time, and temperature on the ligand versus the receptor,
we designed an experiment where the PGG β-glucan was pre-
opsonized with serum at 37°C for 30 min, added to cells that were
resuspended in media supplemented with HI serum (shown in
Figure 4A as non-permissive condition for binding), and we then
subsequently measured rescue of binding to the cells. As described
in the methods section, the percentage of serum carried over along
with the pre-opsonized PGG β-glucan was kept under 2%. Results
in Figure 4A show that the pre-opsonized PGGβ-glucan (OpPGG)
was able to rescue binding on cells in HI serum. While the extent
of rescued binding as measured by MFI and the percentage of cells
positive for BfD IV staining was minimal for unopsonized PGG β-
glucan (PGG) and PGG β-glucan plus serum added separately to
the cells (PGG+ serum), the binding obtained by pre-opsonized
PGG β-glucan was comparable to that observed for cells cultured
FIGURE 3 | Role of complement in binding of PGG β-glucan to human
neutrophils and monocytes. (A) Binding of PGG β-glucan to human
neutrophils and monocytes in 10% serum (upper row) was compared to
binding in 10% HI serum (lower row). Histograms show PGG β-glucan
binding (solid) in comparison to vehicle-control (gray filled). Bar represents
mean MFI from five donors with percentage of inhibition indicated in
parenthesis. **p≤0.05 compared to binding in serum. (B) Inhibitory effect
of C3-inhibitor compstatin on PGG β-glucan binding in neutrophils and
monocytes was measured and compared to that of control peptide-treated
group. Histograms show PGG β-glucan binding in the presence of peptide
control (solid) or compstatin (dotted) in comparison to vehicle-control (gray
filled). Bar represents mean MFI with percentage of inhibition indicated in
parenthesis. **p≤0.05 compared to binding in control peptide. Data
shown are representative of at least three independent experiments
performed with cells obtained from different donors.
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with PGG β-glucan in 10% serum. Interestingly, as shown in
Figure 4B, the pre-opsonized PGG β-glucan was also able to bind
to cells resuspended in HI serum within 10 min of incubation,
which required 60 min for naïve PGG β-glucan in 10% serum.
Furthermore, the pre-opsonized PGG β-glucan could even recover
binding on cells resuspended in HI serum at 4°C (Figure 4C), a
condition, which otherwise gave minimal binding. The efficacy
of the pre-opsonization process for PGG β-glucan itself was also
found to be dependent on time, and temperature: longer incuba-
tion time, and higher incubation temperature (physiologic, 37°C)
of the PGG-serum pre-opsonization mixture, resulted in better
rescue of binding to cells (Figure S3 in Supplementary Material).
These results demonstrate that serum, time, and temperature
are critical factors for β-glucan binding to cells from the ligand,
i.e., PGG β-glucan perspective, and do not appear to be relevant
factors for CR3 modulation.
OPSONIZATION OF SOLUBLE PGG β-GLUCAN OCCURS BY
INTERACTION OF COMPLEMENT PROTEINS WITH THE β-GLUCAN
After demonstrating the critical prerequisite of serum opsoniza-
tion of PGG β-glucan in order for cells to bind the glucan, we
further investigated our hypothesis of complement opsonization
of β-glucan by determining the interaction between PGG β-glucan
and one of the major complement opsonins, iC3b, which is also a
CR3 receptor ligand.
First, we reasoned that if PGG β-glucan is being opsonized
by iC3b, then this protein should be detected on the neutrophils
and monocytes that are binding PGG β-glucan. Results shown
in Figure 5A demonstrate increased staining of iC3b on mono-
cytes and neutrophils incubated with PGG β-glucan in media
containing 10% serum in comparison to iC3b staining levels on
cells incubated in media containing 10% serum alone with no
β-glucan present.
We next qualitatively determined by confocal microscopy
whether the β-glucan and iC3b appear on close proximity on cells
binding PGG β-glucan. Results presented in Figure 5B show the
detection of β-glucan and iC3b on a neutrophil using BfD IV and
a mAb against iC3b respectively; both fluorophores are visually
brighter on the PGG β-glucan-treated cell versus the vehicle-
treated cell. Merging of the BfD IV and iC3b mAb fluorescence
emission signals clearly indicates localization of the bound PGG β-
glucan and iC3b protein in very close or identical spatial positions
on a neutrophil.
The results from confocal microscopy were further corrobo-
rated by evaluating the actual physical interaction of PGGβ-glucan
with iC3b. This was performed using (a) solid phase immunoassay
system where the PGG β-glucan was immobilized to a solid
phase, incubated with serum, and then the iC3b protein bound
to the PGG β-glucan was detected by ELISA, and (b) immuno-
precipitation where PGG β-glucan was immunoprecipitated in
fluid-phase from a mixture of the PGG glucan incubated with
serum using the BfD IV as the immunoprecipitating antibody,
and subsequently subjecting the immunoprecipitated material to
flow cytometric detection of co-immunoprecipitated iC3b pro-
tein. The results obtained from the ELISA showed that the fold
increase of iC3b detected on wells with immobilized PGG β-
glucan over that of the background was significantly higher than
FIGURE 4 | Requirement of optimal percentage of serum, incubation
time, and incubation temperature at the ligand level versus the
cellular level. (A) PGG β-glucan-treated with PBS (PGG+PBS), PGG
β-glucan and serum added separately (PGG+ serum), or serum
pre-opsonized PGG β-glucan (OpPGG) were added at concentration
100µg/mL to neutrophils or to PBMC, incubated for 1 h at 37°C in 10%
serum or 10% HI serum, and binding was measured by flow cytometry. (B)
Binding was measured at 37°C after incubating PGG or OpPGG with the
cells for 10 min or 1 h in RPMI containing 10% serum or 10% HI serum. (C)
Binding was measured at 4°C after incubating PGG or OpPGG with cells as
described above. Data shown in the zebra plots with MFI and percentage of
BfD IV positive population are representative of three independent
experiments performed with cells obtained from three different donors.
the fold increase on dextran-bound wells or wells with immo-
bilized PGG β-glucan incubated in HI serum (Figure 5C). In
the immunoprecipitation studies, iC3b protein was pulled-down
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FIGURE 5 | Detection of the complement opsonin, iC3b on the surface
of PGG β-glucan-bound cells. (A) Fluorescence intensity of BfD IV- (upper
row) and anti-iC3b-stained cells (lower row) treated with PGG β-glucan
(solid) in comparison to that of the vehicle-treated control cells (gray filled).
Data shown here are representative of three independent experiments. (B)
Confocal microscopy images of surface staining of PGG β-glucan (middle
panel, in green), iC3b (third panel from left, in red), or the merged image of
PGG and iC3b (far right panel) on PGG β-glucan-treated (upper row), and
vehicle-treated neutrophils (lower row). Neutrophil nuclei stained with DAPI
is shown in blue. Shown here are representative data from two
independent experiments. (C) Direct interaction of iC3b with immobilized
PGG β-glucan in serum or HI serum was evaluated by ELISA. Dextran was
used as control glucan. Bars represent mean fold change values from three
independent experiments. **p≤0.05 compared with PGG
β-glucan-treated with serum. (D) iC3b present in the immunoprecipitated
PGG β-glucan-serum complex was detected by Flow Cytometry. The
histogram shows the comparison of iC3b detected on the beads
pulled-down from the various glucan-serum mixtures (solid) in comparison
to that from the vehicle-serum mixture (gray filled). Data shown are
representative of three independent experiments.
along with the BfD IV-precipitated PGG β-glucan, while no
iC3b was detected when the β-glucan was immunoprecipitated
in HI serum. The absence of iC3b in the immunoprecipitated
dextran-serum mixture indicated that the iC3b interaction was
specific to PGG β-glucan (Figure 5D). Thus, these data pro-
vide evidence that soluble PGG β-glucan becomes opsonized
when incubated with serum by interacting with one of the
complement opsonins, iC3b, and that opsonization plays a
critical role in binding of the PGG β-glucan to neutrophils and
monocytes.
ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION IS PARTIALLY
INVOLVED IN OPSONIZATION OF SOLUBLE PGG β-GLUCAN
In order to evaluate whether the soluble PGG β-glucan, like its
particulate counterparts, requires alternative pathway of comple-
ment activation for opsonization, we first employed the approach
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of differential chelation of divalent cations that are critical for
functioning of the alternative, classical, and lectin complement
pathways. MgEGTA treatment of serum (addition of magnesium
ions in an equimolar concentration to EGTA) allows optimal com-
plement activation by the alternative pathway while completely
inhibiting the calcium sensitive classical and/or lectin pathways
(24, 25, 39–43). As shown in Figure 6A (left side), iC3b deposition
on plate-bound β-glucan was completely inhibited in MgEGTA-
treated serum. Binding to cells by PGG β-glucan pre-opsonized
with either untreated, or MgEGTA-treated serum (and then resus-
pended in media containing HI serum) was also evaluated. Pre-
opsonization of PGGβ-glucan in untreated serum allowed binding
to occur, while the rescue of binding was highly diminished when
the β-glucan was reacted in MgEGTA-treated serum (Figure 6A,
right side). The carried over EGTA did not affect binding of β-
glucan on cells in serum (non-HI) indicating that the inhibition
effect was specifically due to the abolished classical and/or lectin
pathway of complement activity and not due to potential blocking
of CR3 function (data not shown).
In order to further confirm the role of alternative complement
pathway in opsonization and binding of PGG β-glucan, we inves-
tigated the effect of selectively blocking the alternative pathway
on binding of PGG β-glucan. Factor D, the protease critical for
functioning of alternative pathway was blocked using the anti-
Factor D mAb, 166-32. Binding of PGG β-glucan to neutrophils
and monocytes was evaluated using serum treated with either anti-
Factor D or isotype control antibody. Interestingly, as shown in
Figure 6B, blocking of the alternative pathway partially inhibited
binding of the PGG β-glucan to both neutrophils and monocytes.
Prior to evaluating MgEGTA- or 166-32-treated serum in binding
studies with PGG β-glucan, their ability to selectively block either
the EA-activated classical pathway or the CVF-activated alterna-
tive pathway was investigated using the SC5b-9 measurement kit.
As shown in Figure S4A in Supplementary Material, MgEGTA
treatment of the serum completely blocked the classical pathway,
but allowed functioning of the CVF-activated alternative pathway.
Likewise, the 166-32 mAb specifically blocked the CVF-activated
alternative pathway but not the EA-activated classical pathway
(Figure S4B in Supplementary Material).
These data, taken together demonstrate that calcium deple-
tion had a more pronounced inhibition effect on opsonization
and binding of PGG β-glucan. The opsonization and binding of
PGG β-glucan was only partially affected by inhibiting alternative
pathway activation. Binding did not occur in the absence of the
classical or the lectin pathway, even when the alternative pathway
was fully functional. The potential role of the classical or the lectin
pathway in initiating the complement activation was further cor-
roborated by measuring the levels of C4a, one of the complement
proteins produced downstream of interaction of either the C1 pro-
tein with the immune complex (classical pathway), or the MBL
with the mannose containing pathogen surfaces (lectin pathway).
As expected, the results shown in Figure 6C demonstrate that incu-
bation of 10µg/mL of PGG glucan with WB at 37°C for 30 min was
sufficient to activate complement and produce significant levels of
C4a in the plasma. In contrast, the particulate glucan, the pro-
totype activator of alternative pathway of complement activation
did not produce any C4a in the serum.
FIGURE 6 | Role of the alternative complement pathway in binding of
PGG β-glucan to neutrophils and monocytes. (A) The effect of
MgEGTA-treated serum (Mg+EGTA) on iC3b deposition on immobilized
PGG β-glucan was measured by ELISA (left), and on OpPGG preparation
and subsequent binding to neutrophils and monocytes (right) was
measured by flow cytometry. Histograms show binding of OpPGG prepared
with untreated serum (solid), OpPGG prepared with MgEGTA-treated
serum (dotted) and vehicle binding (gray filled) to neutrophils and
monocytes in 10% HI serum. (B) The effect of anti-Factor D Ab, 166-32 on
PGG β-glucan binding to neutrophils and monocytes was measured by flow
cytometry. Histograms show cell binding to PGG β-glucan in the presence
of isotype control (solid) or 166-32 mAb (dotted) in comparison to
vehicle-control binding (gray filled). Data shown are representative of three
independent experiments with serum from three different donors. (C)
Activation of classical or lectin complement pathway as measured by C4a
generation upon stimulation of WB with PGG or particulate β-glucan was
determined by ELISA. Bar represent mean fold change values from three
independent experiments. **p≤0.05 compared to vehicle-treated WB.
DISCUSSION
In order for the particulate and soluble yeast β-glucans to be
used for therapeutic purposes, an understanding of their inter-
actions with human neutrophils and monocytes is required.
In this study, we investigated the binding characteristics of
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Saccharomyces cerevisiae-derived, relatively pure and analytically
well-characterized soluble PGG β-glucan to human neutrophils
and monocytes. This investigation demonstrated that CR3 is the
main receptor on human neutrophils and monocytes for PGG β-
glucan and that the binding of soluble PGG β-glucan to CR3 is
complement-dependent.
The role of complement proteins in the binding of PGG
β-glucan to human neutrophils and monocytes was elucidated
in several different ways. Dependency of binding on serum
(Figure 2A) and abrogation of binding upon heat-inactivation
of serum (Figure 3A) clearly implicated complement. Signif-
icant inhibition of PGG β-glucan binding in the presence of
compstatin-treated serum further validated the role of comple-
ment (Figure 3B). As compstatin, by selectively binding to C3,
inhibits the cleavage of C3 into its activated form C3b, the data
indicated that conversion of C3 into C3b was the critical initial
step required for binding of PGG β-glucan to cells (44).
As the process of activation of complement proteins in the
serum requires optimal reaction time and temperature, it was
not surprising that the binding of PGG β-glucan increased as a
function of incubation time and temperature during incubation
with the cells (Figures 2B,C). Since PGG β-glucan did not bind
to cells at 4°C and the amount of surface-bound PGG β-glucan
increased over the incubation time, it is unlikely that internal-
ization of PGG β-glucan occurred during the tested time-frame.
The pre-opsonization step with PGG β-glucan allowed binding to
occur on the cells in the HI serum at 4°C in 10–30 min, which
are often the conditions used to measure ligand binding to cells
(Figure 4). Internalization of the pre-opsonized PGG β-glucan
need to be investigated by performing binding studies in WB and
extending the incubation time beyond 2 h.
In contrast to our findings, earlier studies demonstrated bind-
ing of a soluble low molecular weight β-glucan to human neu-
trophils in the presence of low concentrations of serum or at
4°C (7, 8). Differences between our findings and those previously
reported could be due to several reasons, including differences
in the sugar, molecular weight, contaminants, or other struc-
tural aspects that drive activity. Since the previous studies used
FITC or radioactive labeling to measure binding, it is also possible
that these labeling techniques may have made detection sensitive
enough to see small amounts of β-glucan bound to cells; in addi-
tion, the effects of further increasing serum, time, or temperature
were never explored. In contrast to our findings, another pub-
lished study using DTAF-labeled PGG β-glucan demonstrated no
binding to human neutrophils (11). This discrepancy is likely due
to the binding studies being performed using concentrations of
β-glucan that were too low (0.5–2µg/mL) to detect binding.
Complement-mediated opsonization involves a covalent bond
formation between the thioester group in C3b, the active frag-
ment of C3 with the hydroxyl groups of carbohydrates or amine
or hydroxyl groups of proteins present in immune complexes and
on the surface of pathogens (45, 46). After C3b deposits on a sub-
strate, it can be proteolyzed to iC3b and then to C3d. Complement
fragments, specifically, C3b and iC3b bound to β-glucan have been
detected on particulate zymosan and intact yeast (1, 26, 47). In
this study, evidence for opsonization of soluble PGG β-glucan was
obtained by detection of iC3b complement protein attached to
cell surface-bound PGG β-glucan and to purified PGG β-glucan
itself using a mAb specific for iC3b (Figures 5A–D). Although
complement activation and opsonization of immune complexes in
fluid-phase is well-described (48, 49), the result of opsonization of
solubleβ-glucan, a fungal PAMP, is novel. As noted, the attachment
of C3b to a pathogen can be via an ester bond on hydroxylated tar-
gets, and it is reasonable that C3b can bind to PGG β-glucan via
covalent interaction with the abundant hydroxyl groups present
on the carbohydrate (50).
The use of natural ligands for CR3 and monoclonal Abs that
bind to and block discrete regions of CR3 have allowed for a greater
understanding of the specific interactions of β-glucans with CR3.
Ross and colleagues demonstrated previously that blocking Abs
to the CR3 I-domain and lectin domain inhibited opsonized
yeast activation of human phagocytes; the opsonized yeast-CR3
interaction was shown to occur via binding of fixed iC3b to the
I-domain as well as by binding of yeast β-glucan to the lectin
domain, giving rise to the term “dual-ligation” receptor (2). In
our study, similar to the finding with opsonized yeast, inhibition
of binding of PGG β-glucan to human neutrophils and mono-
cytes was observed when both the I- and lectin-domains of CR3
were blocked (Figure 1B). However, maximum inhibition of bind-
ing was consistently achieved by blocking the CD18 chain along
with the CD11b chain. These data indicate a probable role of the
CD18 chain in allowing the CD11b chain to attain a conforma-
tion that is conducive to binding both iC3b and β-glucan present
in opsonized PGG β-glucan. This observation is supported by
findings of previous studies where the CD18 subunit has been
shown to be involved in the “inside-out” signaling that brings
about conformational changes within the ligand binding I-domain
(51). Furthermore, binding of iC3b to CR3 was also demonstrated
to be significantly inhibited by mAbs blocking the CD18 chain
(52, 53).
Although Dectin-1 is predominantly a receptor for unop-
sonized particulate glucans, some studies have shown binding of
opsonized zymosan to Dectin-1 based on inhibition of binding
in the presence of soluble laminarin (3, 4, 54, 55). Laminarin, a
seaweed glucan, has routinely been used as a Dectin-1 antago-
nist, however laminarin has also been shown to be a ligand for
CR3 (7, 8). Our attempts at inhibiting binding of PGG β-glucan
in the presence of excess laminarin produced inconclusive results
(unpublished observations).
In addition to C3b and iC3b, it is quite likely that other C3
fragments, including C3dg, the proteolytic breakdown fragment
of iC3b, is also covalently bound to PGG β-glucan. Different frag-
ments show preferential binding to specific complement receptors,
i.e., C3b binds specifically to CR1, C3dg to CR2, and iC3b is recog-
nized by all complement receptors, but binds more avidly to CR3
and CR4 (56). Therefore, PGG β-glucan opsonized with different
C3 degradation fragments has the potential of being recognized by
these other complement receptors expressed on both innate and
adaptive immune cells (Figure 7). It will be interesting to investi-
gate the role of CR1 in particular, because it is a co-factor known
to play a role in the conversion of C3b to iC3b and to C3dg, and
also because earlier studies have shown the co-operativity between
CR1 and CR3 in allowing sustained binding of iC3b-opsonized
pathogens to CR3 (1, 57–59).
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FIGURE 7 | Model of the binding mechanism of PGG β-glucan to
complement receptors on human immune cells. PGG β-glucan has the
ability to activate complement and to be opsonized by C3b, which can then be
degraded to iC3b, and C3dg, which remain covalently bound. Since the
different complement fragments preferentially bind to specific complement
receptors, the opsonized PGG β-glucan has the potential to bind to CR1 via
C3b, or CR3 via iC3b, or CR2 via C3dg. This study demonstrates that
complement opsonization of soluble yeast β-glucan makes it amenable for
recognition by several complement receptors on human innate and possibly,
adaptive immune cells.
In our study, opsonization and binding of PGG β-glucan was
completely inhibited by calcium chelation, and was not rescued
in serum treated with MgEGTA. However, specifically blocking
only the alternative pathway by Factor D antibody partially inhib-
ited binding of PGG β-glucan to both neutrophils and monocytes.
Furthermore, PGG β-glucan was also able to produce the classical
and/or the lectin pathway-specific C4a complement protein when
incubated with WB. These data suggest that the alternative path-
way plays a role in amplifying the complement activation mediated
by PGG β-glucan (Figure 6). It is quite likely that unlike the par-
ticulate form of β-glucan, PGG β-glucan initially activates the
classical or the lectin pathway, and then the nascent C3b feeds
over into the alternative pathway to further amplify complement
activation. Further studies are required to confirm whether the
lectin or the classical pathway is activated by PGG β-glucan.
In summary, our study demonstrates the critical role of comple-
ment in binding soluble yeast β-glucan to human neutrophils and
monocytes. The discovery of the ability of soluble yeast β-glucan to
activate complement and become opsonized expands the horizon
for its immunomodulatory activities as it could be recognized by
several complement receptors on a repertoire of human innate and
adaptive immune cells. It is important to understand the binding
characteristics of a soluble pharmaceutical-grade yeast β-glucan
preparation to human immune cells as several clinical studies for
different therapeutic applications of β-glucan are either under-
way or being developed (http://clinicaltrials.gov/ct2/results?term=
beta+glucan). The results of this investigation could have impli-
cations on the design of basic research as well as clinical research
studies based on the clinical application of soluble yeast β-glucan.
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Figure S1 | Evaluation of donor variability in concentration-dependent
binding of PGG β-glucan. Binding of increasing concentrations of PGG
β-glucan (0, 10, 25, 100, 200, and 400µg/mL) to neutrophils (left) and
monocytes (right) was determined by flow cytometry as described in the
Section “Materials and Methods”. The graphical representation shows the MFI
of PGG β-glucan-bound neutrophils and monocytes; each symbol ( for
neutrophils and • for monocytes) represents one individual from five separate
experiments. The average MFI obtained at each of the concentrations is
indicated by a horizontal bar.
Figure S2 | Evaluation of donor variability in serum-dependent binding of
PGG β-glucan. Binding of 100µg/mL PGG β-glucan to neutrophils (left) and
monocytes (right) at 2, 5, 10, 20, and 50% of serum or 10% heat-inactivated (HI)
serum was determined by flow cytometry as described in the Section
“Materials and Methods”. The graphical representation shows the MFI of PGG
β-glucan-bound neutrophils and monocytes; each symbol ( for neutrophils and
• for monocytes) represents one individual from five separate experiments. The
average MFI obtained at each of the serum concentrations is indicated by a
horizontal bar.
Figure S3 | Requirement of optimal incubation time and incubation
temperature for pre-opsonization of PGG β-glucan in neutrophils. The
optimal temperature (A) and time (B) for OpPGG preparation and subsequent
binding to isolated human neutrophils in HI serum at 37°C for 1 h was evaluated
by flow cytometry. The MFI and percentage of β-glucan-treated, BfD IV positive
cells are indicated in the zebra plots.
Figure S4 | Evaluation of different serum treatments on the prototypical
activators of classical and alternative pathways of complement activation.
The ability of (A) MgEGTA to block EA-activated CP alone and (B) anti-Factor D
antibody, 166-32 to block CVF-activated AP was confirmed by fluid-phase
SC5b-9 ELISA.
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